RecruitingNot ApplicableNCT05976945

Imagery Rescripting as Treatment for Depression

Imagery Rescripting as a Stand-alone Treatment for Depression: a Pilot Study.

Sponsor

University of Amsterdam

Enrollment

10 participants

Start Date

Aug 10, 2023

Study Type

INTERVENTIONAL

Conditions

Major Depressive Disorder Persistent Depressive Disorder

Summary

The goal of this multiple baseline case series study is to test Imagery Rescripting in depression. The main question\[s\] it aims to answer are: * does Imagery Rescripting lead to a reduction of depression and of believability of negative beliefs held by the participants? * does Imagery Rescripting also leads to reductions in worrying and brooding? * Participants will wait for 6-10 weeks (to assess time effects without treatment), followed by 5 weekly preparation sessions, 8-12 weekly Imagery Rescripting sessions, and 5 weeks post-treatment. * Participants will rate the believability of 3-5 core dysfunctional beliefs related to their depression as well as 2 items assessing depression severity on a weekly basis. In addition, they will fill out more extensive questionnaires on depression, worry and brooding before each phase, as well as at 5 weeks post-treatment, and 6 and 12 months follow-up.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria5

Primary diagnosis of MDD as assessed with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (SCID-5)
Total score of 20\* or above on the BDI-II (cut-off score for moderate depression) (Beck et al., 1996). (\*Based on previous research by Brewin et al. (2009) \& Yuen-tin (2017) demonstrating averages of BDI-II: 34-35, in their population.)
Age 18-65
Dutch or English as a first language (or estimated as sufficient to receive treatment in either of these languages without interpreter)
Willingness to participate in the study (signed informed consent)

Exclusion Criteria10

DSM-5 Bipolar disorder, type 1 (current or past); if there has been no manic episode the last year patients will be included
Psychotic disorders (though psychotic features alongside depression will be allowed)
Organic brain disease
Intelligence Quotient (IQ) \< 80
High risk of self-harm or suicide
Current substance abuse severe level
Start of new medication within 2 months before beginning the study (medication used for longer periods can be continued; patients are requested to keep medication stable during the course of the study)
Having received ImRs (either as a stand-alone or embedded in a greater treatment such as cognitive behavior therapy (CBT) or schema therapy) within the last year
No other evidence-based treatment of MDD is allowed during the study.
Not able to plan enough time for weekly therapy sessions (45-60 minutes); weekly measurements (estimate of 5 minutes) and other measurements (estimate of 20 minutes); and the qualitative post-treatment interview (estimate of 60 minutes) during the study period.

Interventions

BEHAVIORALImagery Rescripting

In Imagery Rescripting patients imagine a different sequence of events matching their needs better than what actually happened in traumatic and other adverse (childhood) experiences.